Redeye’s view on the Q1 report. The organic growth was decent, while the gross margin development comprised most of the deviation compared to the results. The cash flow was also strong. We have decreased our sales estimates and adjusted costs slightly for the coming years. We maintain our Base case of SEK 245 (245) and fair value range of SEK 160 – 380 per share

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Cellavision - Trend is still their friend

© Modular Finance, source Nordic Press Releases